pLentiX2-PURO-shLKB1-Hu Citations (2)

Originally described in: An AMPK-independent signaling pathway downstream of the LKB1 tumor suppressor controls Snail1 and metastatic potential.
Goodwin JM, Svensson RU, Lou HJ, Winslow MM, Turk BE, Shaw RJ Mol Cell. 2014 Aug 7;55(3):436-50. doi: 10.1016/j.molcel.2014.06.021. Epub 2014 Jul 17. PubMed Journal

---

Articles Citing pLentiX2-PURO-shLKB1-Hu

Articles
The hexosamine biosynthesis pathway is a targetable liability in KRAS/LKB1 mutant lung cancer. Kim J, Lee HM, Cai F, Ko B, Yang C, Lieu EL, Muhammad N, Rhyne S, Li K, Haloul M, Gu W, Faubert B, Kaushik AK, Cai L, Kasiri S, Marriam U, Nham K, Girard L, Wang H, Sun X, Kim J, Minna JD, Unsal-Kacmaz K, DeBerardinis RJ. Nat Metab. 2020 Dec;2(12):1401-1412. doi: 10.1038/s42255-020-00316-0. Epub 2020 Nov 30. PubMed
Targeting PGM3 as a Novel Therapeutic Strategy in KRAS/LKB1 Co-Mutant Lung Cancer. Lee H, Cai F, Kelekar N, Velupally NK, Kim J. Cells. 2022 Jan 5;11(1). pii: cells11010176. doi: 10.3390/cells11010176. PubMed

If you have published an article using this material, please email us at to have your article added to this page.